New hope for blood cancer patients who failed standard treatment
Disease control
Recruiting now
This early-stage trial is testing a new oral medication called AJ1-11095 for adults with myelofibrosis, a serious bone marrow cancer. The study is for patients whose disease didn't respond well to or came back after standard JAK2 inhibitor treatment. Researchers will determine th…
Phase: PHASE1 • Sponsor: Ajax Therapeutics, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC